{"id":2159,"date":"2007-09-03T13:21:59","date_gmt":"2007-09-03T12:21:59","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2159"},"modified":"2013-09-12T17:09:09","modified_gmt":"2013-09-12T17:09:09","slug":"paediatric-formulation-of-fosamprenavir-approved-in-the-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2159","title":{"rendered":"Paediatric formulation of fosamprenavir approved in the US"},"content":{"rendered":"<p><strong>On 14 June 2007, the Food and Drug Administration approved a new formulation of Lexiva. Lexiva (fosamprenavir calcium) is now available as an oral suspension (50-mg\/mL).<\/strong><\/p>\n<p>The package insert was updated to include information on this new formulation and to provide dosing information for pediatric patients and patients with hepatic impairment.<\/p>\n<p>For full prescribing information see the product information:<\/p>\n<p><a href=\"http:\/\/www.lexiva.com\">http:\/\/www.lexiva.com<\/a><\/p>\n<p>Source: FDA list serve<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 14 June 2007, the Food and Drug Administration approved a new formulation of Lexiva. Lexiva (fosamprenavir calcium) is now available as an oral suspension (50-mg\/mL). The package insert was updated to include information on this new formulation and to &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-2159","post","type-post","status-publish","format-standard","hentry","category-paediatric-care"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2159"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2159\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}